Merz Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MERZ PHARMS, and when can generic versions of MERZ PHARMS drugs launch?
MERZ PHARMS has four approved drugs.
There are six US patents protecting MERZ PHARMS drugs.
There are ninety-one patent family members on MERZ PHARMS drugs in twenty-two countries and nine supplementary protection certificates in six countries.
Summary for Merz Pharms
| International Patents: | 91 |
| US Patents: | 6 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Merz Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merz Pharms | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 8,945,612 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Merz Pharms | ERYMAX | erythromycin | SOLUTION;TOPICAL | 062508-002 | Jul 11, 1985 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Merz Pharms | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | RE43711 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Merz Pharms | AMPYRA | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 022250-001 | Jan 22, 2010 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ||||
| Merz Pharms | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 8,545,878 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Merz Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merz Pharms | AMPYRA | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 022250-001 | Jan 22, 2010 | 5,370,879 | ⤷ Subscribe |
| Merz Pharms | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 7,182,961 | ⤷ Subscribe |
| Merz Pharms | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 6,514,482 | ⤷ Subscribe |
| Merz Pharms | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 8,586,093 | ⤷ Subscribe |
| Merz Pharms | AMPYRA | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 022250-001 | Jan 22, 2010 | 5,540,938 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MERZ PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 10 mg | ➤ Subscribe | 2014-01-22 |
| ➤ Subscribe | Oral Solution | 1 mg/5 mL | ➤ Subscribe | 2012-06-20 |
International Patents for Merz Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20220054703 | ⤷ Subscribe |
| Japan | 2005511628 | ⤷ Subscribe |
| Spain | 2609482 | ⤷ Subscribe |
| European Patent Office | 2916826 | ⤷ Subscribe |
| South Korea | 102389785 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Merz Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2435025 | LUC00124 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
| 2435024 | 2190014-7 | Sweden | ⤷ Subscribe | PRODUCT NAME: A COMBINATION OF FORMOTEROL INCLUDING ANY PHARMACEUUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, GLYCOPYRROLATE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, AND BUDESONIDE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALT, ESTERS ORSOLVATES THEREOF; REG. NO/DATE: EU/1/20/1498 20201210 |
| 1613296 | 92782 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224 |
| 2435024 | SPC/GB21/029 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: A COMBINATION OF FORMOTEROL, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, GLYCOPYRROLATE, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, AND BUDESONIDE INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ES; REGISTERED: UK EU/1/20/1498 (NI) 20201210; UK PLGB 17901/0352-001 20201210 |
| 2435025 | 19C1040 | France | ⤷ Subscribe | PRODUCT NAME: COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET DE FORMOTEROL (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); NAT. REGISTRATION NO/DATE: EU/1/18/1339 20181220; FIRST REGISTRATION: - EU/1/18/1339 20181220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
